Incidence of Meningococcal Disease Before and After Implementation of Quadrivalent Meningococcal Conjugate Vaccine in the United States
Authors:
Open Access
- 20 July 2020
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Pediatrics
- Vol. 174 (9) , 843-851
Abstract
Meningococcal disease is a serious bacterial infection caused by Neisseria meningitidis leading to high rates of death and disability.1 In the United States, serogroups B, C, and Y cause most meningococcal infections.2 Although the incidence of meningococcal disease is highest in infants, adolescents and young adults have an increased risk of meningococcal disease as well as the highest rates of oropharyngeal carriage, and thus are considered to be the primary source of N meningitidis transmission to other age groups.3 As a result, adolescents are the primary target group for meningococcal vaccination in the United States.Keywords
This publication has 28 references indexed in Scilit:
- Antibody Persistence After Primary and Booster Doses of a Quadrivalent Meningococcal Conjugate Vaccine in AdolescentsThe Pediatric Infectious Disease Journal, 2014
- Antibody Persistence and Booster Response of a Quadrivalent Meningococcal Conjugate Vaccine in AdolescentsThe Journal of Pediatrics, 2014
- Antibiotic prescribing for adults in ambulatory care in the USA, 2007–09Journal of Antimicrobial Chemotherapy, 2013
- Antibody Persistence and Response to a Booster Dose of a Quadrivalent Conjugate Vaccine for Meningococcal Disease in AdolescentsThe Pediatric Infectious Disease Journal, 2013
- Impact of the Serogroup A Meningococcal Conjugate Vaccine, MenAfriVac, on Carriage and Herd ImmunityClinical Infectious Diseases, 2012
- Meningococcal disease: Clinical presentation and sequelaeVaccine, 2012
- Meningococcal carriage by age: a systematic review and meta-analysisThe Lancet Infectious Diseases, 2010
- Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescentsHuman Vaccines, 2010
- Changes inNeisseria meningitidisDisease Epidemiology in the United States, 1998–2007: Implications for Prevention of Meningococcal DiseaseClinical Infectious Diseases, 2010
- Impact of Meningococcal Serogroup C Conjugate Vaccines on Carriage and Herd ImmunityThe Journal of Infectious Diseases, 2008